An indication has been posted on 1 February 2024 in front of the 23andme headquarters in Sunnywell, California.
Justin Sullivan | Getty images
23andme announced on Tuesday that it would voluntarily give voluntarily offering NASDAQ and a release with the US Securities and Exchange Commission from De-Register.
Later this step comes Regeneration pharmaceuticals Earlier this month, it was said that it would acquire “a large extent” of the 23andme assets for $ 256 million.
Drug manufacturer came to the top after a bankrupt auction for 23andme Filed for chapter 11 Insolvency conservation in March.
23andme stated that it would file a delisting form 25 notification with the SEC on or around June 6, which would later remove the stock from registration with listing and nasdac.
The company said that Nasdaq had originally informed the company that one form would be filed in March, but since the exchange has not yet filed the filing, 23andme is voluntarily doing so.
23andme exploded the mainstream due to the DNA test kits of his home, allowing customers to investigate their genetic profiles. At its peak, the company was priced around 6 billion dollars.
But after the merger with a special purpose acquisition company in 2021, the company fought to generate recurring revenue and create viable research or medical businesses.
Rejoronon’s deal is still subject to approval by the US bankruptcy court for the eastern district of Missouri. Pending approval, it is expected to close in the third quarter of this year.
